Capecitabine Teva is a cancer medicine that is used to treat: - colon (large bowel) cancer. Capecitabine Teva is used on its own or with other cancer medicines in patients who have had surgery for stage III or Dukes’ stage C colon cancer; - metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body). Capecitabine Teva is used on its own or with other cancer medicines; - advanced gastric (stomach) cancer. Capecitabine Teva is used with other cancer medicines, including a platinum-containing cancer medicine such as cisplatin; - locally advanced or metastatic breast cancer (breast cancer that has begun to spread to other parts of the body). Capecitabine Teva is used with docetaxel (another cancer medicine) after treatment with anthracyclines (another type of cancer medicine) has failed. It can also be used on its own when treatment with both anthracyclines and taxanes (another type of cancer medicine) has failed or when further treatment with anthracyclines is not suitable for the patient. Capecitabine Teva is a ‘generic medicine’. This means that Capecitabine Teva contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Xeloda. Capecitabine Teva contains the active substance capecitabine.
Therapeutic Indication
### Therapeutic indication Capecitabine Teva is indicated for the adjuvant treatment of patients following surgery of stage III (Dukes’ stage C) colon cancer. Capecitabine Teva is indicated for the treatment of metastatic colorectal cancer. Capecitabine Teva is indicated for first?line treatment of advanced gastric cancer in combination with a platinum?based regimen. Capecitabine Teva in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Capecitabine Teva is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
Therapeutic Area (MeSH)
ATC Code
L01BC06
ATC Item
capecitabine
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| capecitabine | N/A | 卡培他滨 |
EMA Name
Capecitabine Teva
Medicine Name
Capecitabine Teva
Aliases
N/ANo risk management plan link.
